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Abstract
Nucleobindin-1 and nucleobindin-2 are multifunctional proteins that interact with Ca2+, nucleic
acids, and various regulatory proteins in different signaling pathways. So far, our understanding of
the regulation of the biological functions of nucleobindins remains limited. In our proteome-wide
selection for downstream caspase substrates, both nucleobindin-1 and nucleobindin-2 are found to
be the downstream substrates of caspases. We report here the detailed analyses of the cleavage of
nucleobindins by caspases. Significantly, the caspase cleavage sites are located exactly at one of the
Ca2+-binding EF-hand motifs. Our results suggest that the functions of nucleobindins could be
modulated by caspase-mediated cleavage in apoptosis.
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INTRODUCTION
Nucleobindin is a class of EF-hand motif containing Ca2+-binding protein that has multiple
functions. Two nucleobindins have been identified so far, including NUCB1 (or CALNUC,
NUC) and NUCB2 (or NEFA) [1,2]. These two proteins are highly homologous with 62%
amino acid sequence identity, although they are encoded by two separate and unlinked gene
loci. The most characteristic feature of NUCB1 and NUCB2 is the presence of multiple
functional domains, including a signal peptide, a leucine/isoleucine rich region, a putative
nuclear localization signal and a DNA-binding domain, two Ca2+-binding EF-hand motifs, and
a leucine zipper region (Figure 1A).
NUCB1 was first discovered to bind to the nucleosomal-laddered DNA in SLE-prone MRL/
lpr mice during apoptosis [1,3]. Exogenous administration of the recombinant NUCB1 to MRL/
n mice induced autoimmune phenomena and thymic apoptosis, indicating that NUCB1 plays
an important role in inducing autoimmunity and apoptosis. Accumulating evidence suggests
that NUCB1 performs multiple functions through its Ca2+-binding, DNA-binding, and EF-
hand motif mediated interactions with other proteins. It has been shown that NUCB1 is highly
abundant in the Golgi region of a large variety of tissues and could play a key role in Ca2+
homeostasis in the cis-Golgi network and cisternae [2,4,5]. Despite its presence in Golgi,
NUCB1 also possesses features of a transcription factor through the basic amino acid-rich and
the leucine zipper regions [1]. In addition, NUCB1 interacts with multiple binding partners,
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including Gαi3, Gαi2, and cyclooxygenases [6,7]. NUCB2 was originally identified in the
common ALL cell line KM3 [8]. Compared to NUCB1, NUCB2 is 40-residue shorter, but also
present in Golgi, with the Golgi retention motif at the N-terminal leucine/isoleucine-rich region
[9]. Despite their high similarity on the structures of the functional domains, NUCB1 and
NUCB2 are divergent at the N-terminal region, the leucine-zipper, as well as the C-terminal
sequences. NUCB2 was found to interact with necdin and ARTS-1, both through the EF-hand
motifs [10,11]. Clinically, NUCB1 was implicated as a tumor-associated antigen that appeared
to be overexpressed in many colon cancer tissues [12]. On the other hand, NUCB2 was
implicated as an appetite suppressing protein that plays an important role in regulating feeding
behavior in rats [13].
Despite the great importance of NUCB1 and NUCB2 in various signaling pathways, our
understanding of the regulation of their biological functions remains limited. In this research
letter, we show evidence that both NUCB1 and NUCB2 are cleaved by caspases and their
functions mediated by the Ca2+-binding EF-hand motifs could be modulated by caspase-
catalyzed cleavage.
MATERIALS AND METHODS
Generation of radiolabeled NUCB1 and NUCB2 proteins
The DNA templates coding the fragments of NUCB1 and NUCB2 were isolated from our
previous caspase cleavage selections [14]. The coding sequences for full-length NUCB1 and
NUCB2 or their various fragments were PCR amplified from total RNAs of human or zebrafish
using gene specific primers. The PCR products were purified and used as templates for a
coupled in vitro transcription and translation (TNT) reaction in the presence of [35S]-
methionine. Expressed proteins were used for proteolytic cleavage assays.
In vitro proteolytic analysis of radiolabeled NUCB1 and NUCB2 by caspases
An aliquot of TNT reaction mixture was incubated in a caspase reaction buffer (50 mM HEPES,
pH 7.4, 50 mM NaCl, 0.1% CHAPS, 10 mM EDTA, 5% Glycerol, and 10 mM DTT) at 37 °
C for 0.5 to 12 h with 0.1 to 0.5 unit of a caspase of interest (Biovision, Mountain View, CA)
or a caspase pre-inhibited with 10 μM of corresponding tetrapeptide inhibitor (Calbiochem,
San Diego, CA). An aliquot of each reaction mixture was loaded onto a 10% or 15% SDS-
PAGE gel for separation and the signals were detected by autoradiography.
In vitro proteolytic analysis of recombinant NUCB1 His×6-tagged at the N-terminus by
caspases
To determine the cleavage of the N-terminal portion of NUCB1, 1 μg of a recombinant NUCB1
His×6-tagged at the N-terminus (GenWay Biotech, San Diego, CA) was subjected to cleavage
assays by incubation with 0.5 unit of caspase-6 or -8 for 6 h. Alternatively, caspase-6 or -8
were pre-inhibited with Z-VEID-fmk or Z-IETD-fmk, respectively, for 30 min at 37 °C prior
to the addition of recombinant NUCB1. Digestion reactions were resolved by SDS-PAGE gels,
followed by probing with an anti-His×6 antibody (AnaSpec, San Jose, CA).
Ex vivo proteolytic analysis of NUCB1 by caspases
HeLa S3 cells were grown to stationary phase in DMEM media supplemented with 10% FBS.
Cells were harvested and lysed as previously described [14]. Caspase-catalyzed proteolysis of
endogenous NUCB1 was performed by the addition of 0.5 unit of a caspase of interest to the
whole cell extract with 25 μg of total proteins. The reaction mixture was incubated at 37 °C at
various time points in the presence or absence of a caspase inhibitor. Proteins in lysates were
resolved by SDS-PAGE and blots were probed with anti-NUCB1 polyclonal antibody (Aviva
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Systems Biology, San Diego, CA) that recognizes a region (EKKLLERLPEVEVPQHI) near
the C-terminus of human NUCB1.
Cleavage of endogenous NUCB1 during apoptosis under physiological conditions
The in vivo cleavage experiments were performed by the addition of 2 μM or 10 μM CPT
directly to MCF-7 or HeLa S3 cells, which were maintained in the appropriate media. For
cleavage inhibition assays, cells were pre-treated with 50 μM of a tetrapeptide inhibitor for 3
h at 37 °C before a 12 h induction of apoptosis by 2 μM CPT. The inhibitors used were Z-
VAD-fmk (pancaspase inhibitor), 5-[(S)-(+)-2-(Methoxymethyl)pyrrolidino] sulfonylisatin
(caspase-3/7 inhibitor), Z-DEVD-fmk (caspase-3 inhibitor), Z-VEID-fmk (caspase-6
inhibitor), Z-IETD-fmk (caspase-8 inhibitor), Z-LEHD-fmk (caspase-9 inhibitor), and Z-
AEVD-fmk (caspase-10 inhibitor). For time course experiments, MCF-7 or HeLa S3 cells were
treated with CPT up to 36 h. Cells were lysed using a lysis buffer on ice for 1 h [15]. Crude
extracts were cleared by centrifugation at 14,000 RPM for 20 min. Approximately 50 μg of
lysate was loaded into each well, separated by SDS-PAGE, probed with C-terminal anti-
NUCB1 and reprobed with anti-β-actin as a loading control.
RESULTS AND DISCUSSION
Caspase-mediated cleavage of the selected NUCB1 and NUCB2 at the fragment and full-
length levels
To understand which proteins are specifically cleaved by a caspase of interest during apoptosis,
we carried out proteome-wide selections for downstream substrates of different caspase family
members [14]. Interestingly, NUCB1 was isolated from the caspase-6 cleavage selection,
whereas NUCB2 was isolated from both the caspase-3 and caspase-8 cleavage selections.
We first examined whether the selected NUCB1 and NUCB2 fragments were indeed cleaved
by various caspases using radiolabeled NUCB1 and NUCB2 fragments generated by TNT. As
shown in Figures 1B and 1C, the selected NUCB1 and NUCB2 fragments were indeed cleaved
by the caspases used in the selections, respectively, although the cleavage of the selected
NUCB1 fragment was weak. Interestingly, both fragments were also cleaved by other caspases.
The selected NUCB1 fragment could be cleaved by caspase-6 and -8, whereas the NUCB2
fragment could be cleaved by caspase-3, -6, and -8 (Figures 1 B and 1C). In both cases, the
cleavage was completely abolished when the caspase was pre-inhibited with an inhibitor.
We analyzed the sequences of the selected NUCB1 and NUCB2 fragments and mapped their
potential cleavage sites (Figure 1D). The NUCB1 fragment isolated from the selection was
from E186 to N281, which includes a region (233-
EELDGLDPNRFNPKTFFILHDINSDG-258) that contains two potential caspase cleavage
sites (underlined). The observed cleavage by caspase-6 and -8 might occur at DGLDP or
INSDG, although they are not the optimal cleavage sequences. The cleavage site on NUCB1
was further mapped by a combination of different approaches, including using a series of
fragments that contain only one potential cleavage site. Our results indicate that only the
fragment that contains DGLDP site (FG174-460), but not any other fragments out of this region,
was cleaved by caspase-6 and caspase-8 (Figure 1E and data not shown). Therefore, the
cleavage most likely occurs at DGLDP. As for NUCB2, six and five NUCB2 fragments were
isolated from the caspase-3 and caspase-8 cleavage selections, respectively. These 11
sequences have different lengths but all contain E175-L269 as the common region (Figures
1E). The same approaches were used to map the cleavage site at 237-DGLDP-241 (data not
shown).
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To examine the cleavage at the full-length level, we first tested the cleavage of endogenous
NUCB1 by adding purified caspases to the HeLa S3 cell lysate. Figure 2A illustrates that
NUCB1 was cleaved by caspase-3, -6, and -8, and slightly by caspase-7 and -9. Interestingly,
a cleavage product with a molecular weight of approximately 27 kDa was detected. The
observed proteolytic fragment was presumably from the C-terminal area, since the blot was
probed using an anti-NUCB1 antibody that recognizes a region near its C-terminus. We also
used radiolabeled full-length NUCB1 generated by TNT for caspase cleavage analysis (Figure
2B). The results were consistent with that when endogenous NUCB1 was used. Figures 2C
and 2D illustrate that the cleavage of radiolabeled NUCB1 by caspases is fast, with a half-life
of 3 h and 1 h by caspase-6 and -8, respectively.
Since we were not able to detect the expression of full-length NUCB2 by using the commercial
anti-NUCB2 antibodies (Aviva Systems Biology and Abcam), full-length radiolabeled
NUCB2 generated by TNT was used as substrate for proteolysis. As shown in Figure 2E, full-
length NUCB2 was cleaved by caspase-3 and caspase-8 that were used in the selections, with
a half-life around 0.5 h by caspase-8 (Figure 2F). The size of the proteolytic product is also
consistent with a cleavage at the mapped site using the selected NUCB2 fragments.
Intriguingly, full-length NUCB2 thus generated was also cleaved by caspases-6, -7, -9, and
weakly by caspase-10. The cleavage patterns by different caspases were very similar,
suggesting they have the same cleavage sites.
NUCB1 was specifically cleaved during apoptosis under physiological conditions
To examine the cleavage of nucleobindins under in vivo conditions, we induced programmed
cell death in different cell lines by CPT. Western blot analysis, using anti-NUCB1 against the
C-terminus, illustrates that NUCB1 was cleaved during apoptosis as observed by the significant
decrease of the full-length in MCF-7 cells and the appearance of a cleavage fragment in HeLa
S3 cells (Figure 3A). The decrease of NUCB1 in both MCF-7 and HeLa S3 cells was dependent
on the concentration of CPT that was used to induce apoptosis. Figure 3B shows that the
cleavage of NUCB1 during apoptosis in MCF-7 cells is efficient and has a half-life around 9
h following 2 μM CPT treatment. Interestingly, no cleavage product was observed in MCF-7
cells, suggesting that the cleavage products are further degraded in vivo and therefore not
detectable by anti-NUCB1 that recognizes the C-terminus. In contrast, a proteolytic product
was observed in HeLa S3 lysates (Figure 3A, right panel), presumably because different cell
lines could behave differently after the induction of apoptosis by CPT.
The in vivo cleavage of NUCB1 was caspase-specific and completely inhibited by a caspase-8,
caspase-9, or caspase-10 inhibitor (Figure 3C). Although our in vitro and ex vivo results indicate
that NUCB1 was digested efficiently by caspase-3, -6 and -8 (Figures 2A and 2B), it is of great
interest to examine which caspase plays a major role in cleaving NUCB1 during apoptosis
under in vivo conditions. Since caspase-3 is not functional in MCF-7 cells [16], it is unlikely
that caspase-3 is involved in the in vivo cleavage of NUCB1. Interestingly, NUCB1 digestion
still occurred when the cells were pre-treated with a caspase-6 or caspase-3/-7 inhibitor,
suggesting these caspases are less likely to play a major role in cleaving NUCB1. By combining
the results of in vitro cleavage (Figures 2A and 2B) and of in vivo inhibition analyses (Figure
3C), the observed in vivo cleavage of NUCB1 in MCF-7 cells is likely mediated by caspase-8,
although the role of other caspases could not be completely ruled out. It is worth mentioning
that we were not able to detect the cleavage of NUCB1 in cells that were not subjected to an
apoptotic stimuli, suggesting the cleavage of NUCB1 by the basal caspase activity is below
the detection limit.
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The conservation of the caspase cleavage sites on nucleobindins in different species
We analyzed the conservation of the putative caspase cleavage sites on both NUCB1 and
NUCB2 in different species (Figure 4A). Compared to human NUCB1, the NUCB1 orthologs
from bovine, rat, and mouse have amino acid sequence identities at 89%, 87%, and 87%,
respectively. The cleavage-site containing E233-G258 region is identical among these four
species. NUCB2 is also highly conserved among different mammalian species, with the
identical DGLDP site. These results suggest that the cleavage of NUCB1 and NUCB2 by
caspases is highly conserved in different species.
It appears that the mapped DXXD cleavage site is also conserved in other species, including
in fish and fly. To test whether a nucleobindin protein from a non-mammalian species could
be indeed cleaved by its cognate caspase, we synthesized the full-length zebrafish NUCB2 (Z-
NUCB2, FL1-496) and the putative cleavage site-containing fragment (FG151-295) and used
them as substrates for the recombinant zebrafish caspase-3 [17]. Figure 4B illustrates that both
the full-length and the fragment of Z-NUCB2 were efficiently and specifically cleaved by
zebrafish caspase-3. Interestingly, the cleavage was more efficient by zebrafish caspase-3 than
by human caspase-3, suggesting that Z-NUCB2 might be a physiological caspase-3 substrate
in zebrafish. However, the evolutionary conservation of the caspase cleavage sites on NUCBs
does not necessarily mean that such conservation has got to do with a function. More
investigation should be done to address the question.
Implication of the regulation of Ca2+-signaling on NUCB1 and NUCB2 by caspase-mediated
cleavage
As shown in Figure 1A, multiple functional domains are present on both NUCB1 and NUCB2
[1]. It appears that the multiple functions of NUCB1 and NUCB2 are partitioned at the first
and the second halves of the proteins. The first half contains a signal peptide, a leucine/
isoleucine rich region and a putative nuclear targeting signal. Therefore, this half of the
nucleobindins is important for their subcellular localization. It has been reported that a NUCB2
mutant lacking the N-terminal leucine/isoleucine-rich region failed to be retained in the Golgi,
whereas the deletion of all the other domains or regions had no effect [9]. The second half of
nucleobindins contains two EF-hand motifs and a C-terminal leucine-zipper motif, which are
critical in sensing the Ca2+ signal, interacting with a number of binding partners, and
associating with DNA.
The caspase cleavage sites we identified on NUCB1 and NUCB2 are within the region of
residues 235-255. In both nucleobindins, such cleavage sites are exactly located at the
beginning of the first Ca2+-binding EF-hand motif that is just downstream of the putative
bipartite nuclear targeting signal. It has been demonstrated that the EF-hand motifs on NUCB1
and NUCB2 are very important for their binding with Ca2+ and also interaction with a number
of other binding partners, including Gαi3, Gαi2, cyclooxygenases, necdin and ARTS-1.
Therefore, it is likely that such functions could be affected by caspase-mediated cleavage.
However, which specific functions of EF-hand motif are disrupted remains to be addressed.
The caspase-mediated cleavage will presumably truncate the nucleobindins into at least two
pieces. Such cleavage will decouple the functional domains on the first and the second halves
that are otherwise well integrated. After the cleavage, the second half is less likely to be retained
in Golgi apparatus or translocated to nucleus, due to the removal of the N-terminal Golgi
retention domain and the nuclear targeting signal. In light of this hypothesis, we traced the fate
of the N-terminal portion of NUCB1 by using an N-terminal His×6-tagged NUCB1. It was
found that the N-terminal tagged NUCB1 was rapidly degraded in vivo. Therefore, we
addressed the question by incubating a recombinant NUCB1 His×6-tagged at the N-terminus
with purified caspase-6 or -8 (Figure 3D). The result shows that a major fragment is produced
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from such a cleavage, with a size consistent with a cleavage at the mapped site. Due to the
rapid degradation of the N-terminal tagged NUCB1 in mammalian cells, the physiological role
of the N-terminal region should be addressed using antibodies that specifically recognize the
N-terminus of the endogenous protein or using caspase-resistant mutants. Future work will be
directed to investigate the role of the N-terminus, the regulation of the biological functions of
NUCB1 and NUCB2 by Ca2+ signals and by caspases under physiological conditions.
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Schematic representation of the functional domains on human NUCB1 and NUCB2 (A) and
in vitro cleavage of the selected NUCB1 (B) and NUCB2 (C) fragments (FG) by caspase-3,
-6, -7, and -8. The radiolabeled protein fragments were generated by TNT. EF-H: Ca2+-binding
EF-hand motif; L-ZP: leucine-zipper motif; I: caspase-3 inhibitor Ac-DEVD-fmk. The black
dot between two EF-hand motifs represents an acidic region. The putative cleavage site is
indicated by a red arrow. (D): The sequences of the NUCB1 and NUCB2 fragments isolated
from different caspase cleavage selections. (E): Cleavage site mapping using radiolabeled
NUCB1 fragments that cover different regions.
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The caspase cleavage specificity and time course of full-length nucleobindins. (A): Ex vivo
caspase cleavage specificity of endogenous full-length NUCB1 from HeLa S3 lysate. (B): In
vitro cleavage specificity of radiolabeled full-length NUCB1 generated by TNT. (C): In
vitro cleavage time course of radiolabeled full-length NUCB1 by caspase-6. (D): In vitro
cleavage time course of radiolabeled full-length NUCB1 by caspase-8. (E): In vitro caspase
cleavage specificity of radiolabeled full-length NUCB2. (F): In vitro cleavage time course of
radiolabeled full-length NUCB2. Endogenous NUCB1 was probed using an anti-NUCB1
antibody that recognizes its C-terminus. All radiolabeled NUCBs were detected through
autoradiography. Negative controls without using any caspase or with a pre-inhibited caspase
were labeled as “-” and “Inh”, respectively.
Valencia et al. Page 9














In vivo analysis of NUCB1 cleavage in MCF-7 and HeLa S3 cells and in vitro N-terminal
digestion tracking of recombinant NUCB1. (A): Cleavage of NUCB1 in MCF-7 (left panel)
and HeLa S3 (right panel) cells after a 12 h or 36 h induction with various concentrations of
CPT. (B): Western blot analysis of the time-dependent cleavage of NUCB1 after the induction
of apoptosis by 2 μM CPT in MCF-7 cells. (C): In vivo inhibition assay using different caspase
inhibitors. Cells were pre-treated with 50 μM of various inhibitors prior to the induction of
apoptosis with 2 μM of CPT (bottom panel). The inhibitors used were Z-VAD-fmk, 5-[(S)-
(+)-2-(Methoxymethyl)pyrrolidino] sulfonylisatin, Z-VEID-fmk, Z-IETD-fmk, Z-LEHD-
fmk, and Z-AEVD-fmk for pancaspase, caspase-3/-7, caspase-6, caspase-8, caspase-9, and
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caspase-10, respectively. NUCB1 was probed using an anti-NUCB1 antibody that recognizes
its C-terminus. (D): Tracking the cleavage of the N-terminal portion of NUCB1. N-His×6-
NUCB1 was digested with caspase-6 or –8 or caspases pre-inhibited with the appropriate
inhibitor. Blots were probed with an anti-His×6 antibody.
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(A): Alignment of the selected, cleavage site-containing human NUCB1 and NUCB2
fragments with the corresponding regions on their orthologs from other species. The conserved
caspase recognition sites are highlighted in red. Non-conserved residues are marked in yellow.
The putative DQYD cleavage site on C. elegans NUCB is underlined. (B): In vitro cleavage
of zebrafish NUCB2 full-length or putative cleavage site-containing fragment by zebrafish
caspase-3 (ZCASP3) and by human caspase-3 (HCASP3). Ac-DEVD-CHO was utilized as an
inhibitor of ZCASP3.
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